EU Certifies Zebra’s AI Systems for Brain Bleeds & Pneumothorax

EU Certifies Zebra’s AI Systems for Brain Bleeds & Pneumothorax
Share this:

Zebra Medical Vision recently revealed that two of its imaging products had received CE certification in Europe, to expedite diagnosis and review of critical conditions, especially in medical imaging.

The company’s AI technology has the potential of flagging time-sensitive cases like brain bleed in CT scans and pneumothorax in chest X-rays.

According to the company, the technology minimizes the duration taken by ER staff and radiologists in identifying critical conditions by 80 percent.

As such, it helps in improving the timeliness and quality of treatment.

The imaging analytics engine from Zebra not only links to any given medical picture archive system but also analyzes the necessary scans using its algorithms.

SEE MORE: Top 10 Ways Artificial Intelligence is Impacting Healthcare

After a critical condition is detected, a typical message helps to alert several systems in the hospital including the emergency room worklists and the radiology department.

Every hospital can modify the way the alert appears, either with priority ranking or color coding, and the technology can be deployed via the cloud or on-premises.

Pneumothorax, which is the existence of gas within the pleural space that appears between the chest wall and the lung, is still a huge health problem globally with massive associated healthcare and morbidity costs.

SEE MORE: World Top 25 Artificial Intelligence Companies

Without fast management, the condition can cause a complete collapse of the lungs and other potentially lethal complications.

Pneumothorax can either be spontaneous or be triggered by underlying complications, trauma, and lung disease from surgical procedures or biopsies.

With an incidence rate of approximately 18 to 28 cases for a population size of 100,000, there are between 130,000 and 207,000 pneumothorax cases in Europe each year.

Late-diagnosis or misdiagnosis of pneumothorax affects nearly 74,000 Americans annually.

Brain bleed is more common, and it is the main cause behind almost 8-15 percent of all the strokes in western nations.

It affects about 3.6 million Americans per year.

The Cleveland Clinic revealed that stroke is the fifth-top cause of death in the US.

In fact, intracranial hemorrhage is behind 10% of the stroke cases in the United States.

Brain bleeds can affect people of different age groups.

Even though hemorrhagic stroke and cerebral hemorrhage are typically associated with elderly adults, they can also strike children.

“In a clinical validation study we performed, Zebra-med’s acute CXR pneumothorax and CT Brain bleed products demonstrated a promising potential to substantially reduce turn-around time and increase the radiologist’s confidence in making these diagnoses”

said Dr. Terry Matalon, chairman of diagnostic radiology at Albert Einstein Medical Center, in the statement.

SEE MORE: Artificial Intelligence in Medicine – Top Applications

In 2018, Zebra was granted eight CE marks for several algorithms and FDA clearance, specifically for its Coronary Calcium Scoring algorithm, enabling the company to grow its presence in the United States.

To date, the company has fundraised more than $50 million from investors in three different financing rounds.

Artificial intelligence is mostly being leveraged in detecting illnesses from scans- Sir John Bell revealed in 2018 that AI-powered systems could save billions of money for the National Health Service (NHS), reducing the service’s £2.2 billion expenditure on pathology by half through detecting typical illnesses from scans.

Share this:

Leave a Reply

avatar
  Subscribe  
Notify of